ReviewFrontiers in neuroscience2025
Tank-binding kinase 1 regulates inflammation and autophagy in glaucoma.
Review in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
TANK-binding kinase (TBK1) copy number variations have been identified as a monogenic cause of familial normal tension glaucoma (NTG). While elevated intraocular pressure (IOP) is a common risk factor in primary open angle glaucoma (POAG), NTG develops in the absence of IOP elevation. The current available standard of care for glaucoma is lowering IOP, highlighting the need to explore alternative therapeutic mechanisms. The established roles of TBK1 in nuclear factor kappa B (NF-κB) and interferon regulatory factor (IRF) signaling, as well as its involvement in autophagy, suggest it may contribute to glaucomatous neurodegeneration by exacerbating retinal ganglion cell (RGC) stress and optic nerve (ON) damage. This review aims to consolidate current knowledge on the contribution of TBK1 to glaucomatous pathology, focusing on its genetic and molecular roles. By identifying gaps in understanding, this work seeks to guide future research efforts into the mechanisms underlying TBK1's influence on NTG and to explore therapeutic strategies targeting its pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.